- Home
- PFO vs RENB Comparison
PFO vs RENB Comparison
Compare PFO & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFO
- RENB
- Stock Information
- Founded
- PFO 1991
- RENB 2011
- Country
- PFO United States
- RENB United States
- Employees
- PFO N/A
- RENB N/A
- Industry
- PFO Finance Companies
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- PFO Finance
- RENB Health Care
- Exchange
- PFO Nasdaq
- RENB Nasdaq
- Market Cap
- PFO 123.7M
- RENB 101.3M
- IPO Year
- PFO N/A
- RENB N/A
- Fundamental
- Price
- PFO $9.11
- RENB $0.60
- Analyst Decision
- PFO
- RENB
- Analyst Count
- PFO 0
- RENB 0
- Target Price
- PFO N/A
- RENB N/A
- AVG Volume (30 Days)
- PFO 31.8K
- RENB 335.9K
- Earning Date
- PFO 01-01-0001
- RENB 11-19-2024
- Dividend Yield
- PFO 6.51%
- RENB N/A
- EPS Growth
- PFO N/A
- RENB N/A
- EPS
- PFO N/A
- RENB N/A
- Revenue
- PFO N/A
- RENB N/A
- Revenue This Year
- PFO N/A
- RENB N/A
- Revenue Next Year
- PFO N/A
- RENB N/A
- P/E Ratio
- PFO N/A
- RENB N/A
- Revenue Growth
- PFO N/A
- RENB N/A
- 52 Week Low
- PFO $6.90
- RENB $0.40
- 52 Week High
- PFO $8.51
- RENB $5.25
- Technical
- Relative Strength Index (RSI)
- PFO 42.14
- RENB 49.62
- Support Level
- PFO $9.14
- RENB $0.56
- Resistance Level
- PFO $9.49
- RENB $0.64
- Average True Range (ATR)
- PFO 0.11
- RENB 0.07
- MACD
- PFO -0.00
- RENB 0.00
- Stochastic Oscillator
- PFO 18.92
- RENB 46.07
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end investment company. Its primary investment objective is to produce high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.